SCHEMBL4251004

SCHEMBL4251004

COC(=O)[C@]1(C)OC[C@H](c2ccc(OCCOc3ccc(Oc4ccccc4)cc3)cc2)CO1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.44
MAPT P10636 1/20 0.44
LTA4H P09960 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PPARA Q07869 3/20 0.41
HTR1A P08908 2/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
PPARG P37231 2/20 0.40
PPARD Q03181 2/20 0.40
HRH3 Q9Y5N1 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MMP3 P08254 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4243663 1.00 RAB9A (0.44) RAB9AMAPTLTA4HCYP1A2CYP2C9
SCHEMBL4250701 0.90 PPARA (0.46) RAB9AMAPTLTA4HPPARAPPARG
SCHEMBL4250184 0.90 PPARA (0.46) RAB9AMAPTLTA4HPPARAPPARG
SCHEMBL4250178 0.90 PPARA (0.46) RAB9AMAPTLTA4HPPARAPPARG
SCHEMBL4254622 0.85 PPARG (0.52) RAB9AMAPTLTA4HCYP1A2CYP2C9
SCHEMBL4244878 0.85 PPARG (0.52) RAB9AMAPTLTA4HCYP1A2CYP2C9
SCHEMBL4250294 0.85 ADAM17 (0.49) RAB9ACYP1A2
SCHEMBL4247217 0.85 ADAM17 (0.49) RAB9ACYP1A2
SCHEMBL5440996 0.85 LTA4H (0.44) RAB9AMAPTLTA4HCYP1A2CYP2C9
SCHEMBL5455623 0.84 PPARA (0.44) RAB9AMAPTLTA4HCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012069-A1 Novel Antidiabetic Compounds CADILA HEALTHCARE LIMITED (IN) 2009-01-08 US claimed
US-20090012069-A1 Novel Antidiabetic Compounds CADILA HEALTHCARE LIMITED (IN) 2009-01-08 US disclosed
EP-1781633-A1 NOVEL ANTIDIABETIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2007-05-09 EP disclosed
WO-2006018855-A1 NOVEL ANTIDIABETIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012069-A1 Novel Antidiabetic Compounds GPR119, SLC5A1, SLC5A2 RAB9A 2237/4885MAPT 110/4885LTA4H 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.